H.I.G. Capital News
-
NORTHBROOK, IL AND GREENWICH, CT - September 16, 2021 - Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and McGill University…
-
NORTHBROOK, IL and GREENWICH, CT - September 9, 2021 - Clarus Therapeutics, Inc., a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women (“Clarus”), and Blue Water Acquisition Corp.…
-
June 1, 2021 - Neurana Pharmaceuticals Appoints Georgia Erbez and Liz Cermak to Board of Directors
SAN DIEGO – June 1, 2021 – Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the appointment of Georgia Erbez and Elizabeth (Liz) Cermak to its Board of Directors. Ms. Erbez and Ms. Cermak are accomplished, experienced…
-
WEST LAFAYETTE, IN – May 20, 2021 - On Target Laboratories, Inc., a privately held biotechnology company developing fluorescent markers to target and illuminate cancer during surgery, today announced results of the 006 Study, a Phase 3, randomized, multi-center, prospective, open-label…
-
NORTHBROOK, IL AND GREENWICH, CT – April 27, 2021 - Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and Blue Water Acquisition Corp. (NASDAQ: BLUW)…
-
CHICAGO – March 30, 2021 – Augmedics, a pioneer in augmented reality surgical image guidance, announced today that it has raised $36 million in an over-subscribed Series C financing with an international syndicate of Israel-US investors. This comes only eight months after the company…
-
MALVERN, PA & SAN DIEGO – March 11, 2021 – PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract…
-
ZUG, SWITZERLAND – January 21, 2021 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system (CNS) disorders, today announced that the Committee for Medicinal Products for Human Use…
-
MARLBOROUGH, MA – January 12, 2021 - CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that Chief Executive Officer & President Burke T. Barrett will present at the 23rd Annual ICR Conference,…
-
MARLBOROUGH, MA – January 11, 2021 – CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to…
-
ROME – January 4, 2021 – Angelini Pharma, an international pharmaceutical company which is a part of the private ItalianAngelini Group – and Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovativetreatments…
-
SAN DIEGO – December 21, 2020 – Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that the first patient has been enrolled in the Phase 3, RESUME-1, clinical study of tolperisone, a novel, non-opioid, centrally…
-
SAN DIEGO – December 8, 2020 – Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscularconditions, today announced positive top-line results from the Phase 1 central nervous effects (CNS) clinical study of tolperisone. Thestudy, utilizing a validated…
-
November 24, 2020 - Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research
SAN DIEGO – November 23, 2020 - Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the publication of results from the dose-ranging Phase 2 STAR Study of tolperisone in patients with acute and painful muscle spasms…
-
BRIDGEWATER, NJ - October 22, 2020 – Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection in a ready-…